Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PCSK9 Inhibitors' First Birthday Brings Sluggish Sales And More Bad Press

Executive Summary

Analysis published in the Journal of the American Medical Association is the latest to argue that PCSK9 inhibitors are not cost-effective.

Advertisement

Related Content

Amgen Says Repatha Outcomes Trial Backs Up Its Pricing Math
Will Physician Demand For Repatha Put Pressure On Payer Restrictions?
Is Amgen's FOURIER Enough For Physicians, Payers To Expand Repatha Use?
4Q Pharma Results Preview, Part 2: Pfizer, Lilly, Roche, AstraZeneca, Merck, Amgen, Novo
Regeneron Emphasizes Pipeline Promise As Eylea Pricing Pressure Builds
Amgen Plugs Away On Repatha, With Hope For New Monthly Product
PCSK9 Sponsors, Payers In The Ring At ACC
Amgen’s Statin Intolerance Study May Not Cure What Ails PCSK9 Inhibitors
PCSK9 List Price Discounts Of 67% To 85% Suggested By ICER Analysis
Formulary Focus: PCSK9 Drug Prices May Lead Payers To Impose Coverage Restrictions

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097136

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel